Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (GKOS) is a leader in ophthalmic medical technology, pioneering micro-invasive glaucoma surgery (MIGS) and transformative eye care solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access timely press releases covering product approvals, financial results, and research developments directly impacting glaucoma treatment paradigms. Our curated collection includes updates on therapeutic innovations, partnership announcements, and progress in addressing various stages of ocular disease.
Bookmark this page for streamlined access to Glaukos' latest achievements in medical device engineering and surgical techniques. Regularly updated content ensures you stay informed about developments influencing both patient care and the evolving ophthalmic technology landscape.
Glaukos Corporation (NYSE: GKOS) reported Q4 2022 net sales of $71.2 million, a 3% decline from Q4 2021. Glaucoma and Corneal Health net sales were $52.9 million and $18.3 million, respectively. Gross margin was approximately 76%, down from 77% in the previous year. SG&A expenses rose by 9% to $51.9 million, while R&D expenses surged 34% to $35.8 million. The net loss was $31.5 million, or ($0.66) per diluted share. For full year 2022, net sales totaled $282.9 million, a 4% decline year-over-year. The company provided 2023 net sales guidance of $290 million to $295 million, anticipating challenges from the macroeconomic environment.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will participate in the Citi Healthcare Conference on March 1, 2023, at 1:15 p.m. ET, in New York City. The event will include a live and archived webcast accessible on the company's Investors website. Glaukos specializes in developing innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since its initial commercial launch in 2012. The company aims to enhance standard care through its diverse platforms for medical device and pharmaceutical innovations.
Glaukos Corporation (NYSE: GKOS) will announce its fourth quarter and full year 2022 financial results after market close on
Investors can access the live webcast via Glaukos' investor relations website.
Glaukos Corporation (NYSE: GKOS) announced positive results from a multi-center clinical trial assessing the iDose TR exchange procedure for patients previously treated with the implant. The trial showed that a second administration of iDose TR was safe, with no subjects experiencing over 30% endothelial cell loss over an average of 5.2 years. The company plans to include these results in its FDA New Drug Application submission in Q1 2023. Glaukos aims to improve glaucoma treatment paradigms with this innovative technology.
Glaukos Corporation (NYSE: GKOS) announced significant developments in its clinical pipeline, including the start of subject enrollment for a Phase 3 confirmatory trial of Epioxa™ for keratoconus treatment and positive Phase 2a results for GLK-301 for Dry Eye Disease. The latter demonstrates improved tear film quality and vision. Approximately 290 subjects will be randomized in the Epioxa trial, targeting completion by the end of 2023. These milestones are expected to propel advancements in Glaukos' innovative therapies for chronic eye diseases.
Glaukos Corporation (NYSE: GKOS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. This event highlights Glaukos' focus on innovation in ophthalmic medical technology and pharmaceuticals, specifically targeting glaucoma and other ocular disorders. A live and archived webcast will be available on their investor relations website, providing insights into their ongoing development of novel therapies and medical devices aimed at advancing treatment standards.
Glaukos Corporation (NYSE: GKOS) announced management's participation in the Stephens Annual Investment Conference on November 16, 2022, at 2:00 p.m. CT in Nashville, TN. The event will be accessible via a live and archived webcast on their Investors section of the website. Glaukos specializes in ophthalmic medical technology and pharmaceuticals, focusing on innovative treatments for glaucoma, corneal disorders, and retinal diseases. They pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance glaucoma treatment.
Glaukos Corporation (GKOS) reported third-quarter 2022 net sales of $71.3 million, a decline of 4.6% year-over-year. The glaucoma segment generated $53.7 million, while corneal health contributed $17.5 million. Gross margin was approximately 76%, down from 79% in Q3 2021. SG&A expenses rose 6% to $47.1 million, and R&D expenses slightly increased. The net loss was $27.6 million or ($0.58) per diluted share. The company updated its 2022 net sales guidance to $278 million to $280 million. Glaukos ended the quarter with approximately $371 million in cash and equivalents.
Glaukos Corporation (NYSE: GKOS) announces its third quarter 2022 financial results will be released after market close on November 2, 2022. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET) for management to discuss the results. The company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012. A replay of the call will be available on Glaukos' website post-event.
Glaukos Corporation (NYSE: GKOS) announces its participation in the American Academy of Ophthalmology (AAO) annual meeting, September 30 - October 3, 2022, in Chicago, IL. The company will showcase advancements in glaucoma and corneal health technologies. Key topics include novel intraoperative OCT use, trabecular bypass surgery efficacy, and corneal health presentations. Glaukos will exhibit at booth #4503, highlighting their commitment to innovative ophthalmic treatments. Further details and abstracts are available on the AAO website.